Meeting
2013 ASCO Annual Meeting
Pimasertib plus gemcitabine in metastatic pancreatic adenocarcinoma: Results of a safety run-in part of a phase II trial.
Authors
Chris Verslype
UZ Leuven, Gasthuisberg Campus, Leuven, Belgium
Chris Verslype , Pascal Hammel , Manuel Hidalgo , Teresa Macarulla , Rocio Garcia-Carbonero , Thierry André , Marc Van Den Eynde , Berta Laquente Saez , Michele Milella , Eric Raymond , Thea Faivre , Alvin Milner , Dolores Tarabaric , Giuseppe Locatelli , Oliver von Richter , Bernard Laffranchi , Eric Van Cutsem
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
2009-011992-61
Citation
J Clin Oncol 31, 2013 (suppl; abstr 4041)
DOI
10.1200/jco.2013.31.15_suppl.4041
Abstract #
4041
Poster Bd #
16C
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase Ib study of a novel, small-molecule MDM2 inhibitor APG-115 combined with pembrolizumab in U.S. patients with metastatic solid tumors.
First Author: Anthony W. Tolcher
Poster
2016 Gastrointestinal Cancers Symposium
A phase Ib dose escalation, safety, and tolerability study of sonidegib in combination with gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma.
First Author: Teresa Macarulla
Poster
2024 ASCO Annual Meeting
QUIC: Phase 2 study of gemcitabine, cisplatin, quemliclustat (AB680), and zimberelimab (AB122) during first-line treatment of advanced biliary tract cancers (BTC)—Big Ten Cancer Research Consortium study BTCRC-GI22-564.
First Author: John Ebben
Poster
2024 ASCO Annual Meeting
![EMITT-1: Proof-of-mechanism immunopeptidome (ImPD) effects at target PK exposure, in a phase 1 study of GRWD5769 (a first-in-class inhibitor of Endoplasmic Reticulum Aminopeptidase 1 [ERAP1]) in patients with solid malignancies.](https://d201v5jt9ylckg.cloudfront.net/316/15821/233888/233888_A322_poster_pv.jpg)
EMITT-1: Proof-of-mechanism immunopeptidome (ImPD) effects at target PK exposure, in a phase 1 study of GRWD5769 (a first-in-class inhibitor of Endoplasmic Reticulum Aminopeptidase 1 [ERAP1]) in patients with solid malignancies.
First Author: Thomas Lillie